C12Y 305/01015
Aspartoacylase
Official title: Aspartoacylase (3.5.1.15)
C12Y305/01015 (Aspartoacylase) appears on 23 US grants and 37 published applications in this corpus.
Search patents in C12Y- Granted patents
- 23
- Published applications
- 37
- Assignees
- 11
- Inventors
- 31
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 3 | 4 |
| 2018 | 1 | 4 |
| 2019 | 4 | 7 |
| 2020 | 1 | 3 |
| 2021 | 2 | 1 |
| 2022 | 5 | 4 |
| 2023 | 0 | 5 |
| 2024 | 2 | 0 |
| 2025 | 2 | 2 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Targeting peptides for directing adeno-associated viruses (AAVs)16 Jun 2026US 12,653,904 B2California Institute of Technology
- Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of N-acetyl-aspartic acid6 Jan 2026US 12,514,911 B2Rowan University
- Methods of treating or preventing amyotrophic lateral sclerosis30 Dec 2025US 12,508,327 B2Rowan University
- Methods and compositions for treating metabolic imbalance in neurodegenerative disease9 Dec 2025US 12,491,235 B2University of Massachusetts
- Engineered parasites for delivering protein to the central nervous system (CNS)27 Aug 2024US 12,070,476 B2Ramot at Tel-Aviv University Ltd.
- Methods of Treating or Preventing Amyotrophic Lateral Sclerosis19 Mar 2026US 2026/0077060 A1Rowan University
- Methods and compositions for treating metabolic imbalance in neurodegenerative disease19 Feb 2026US 2026/0048104 A1University of Massachusetts
- Methods and compositions for treating leukodystrophies19 Feb 2026US 2026/0048146 A1
- Use of endogenous aspartoacylase promoter elements for tissue-restricted expression of gene therapies14 Aug 2025US 2025/0255987 A1University of Massachusetts
- Engineered parasites for delivering protein to the central nervous system (cns)20 Feb 2025US 2025/0057892 A1Ramot at Tel-Aviv University Ltd.
Most cited
By later US patents
- Recombinant AAV capsid protein95US 9,585,971 B2California Institute of Technology · 2017
- CNS targeting AAV vectors and methods of use thereof91US 9,102,949 B2University of Massachusetts · 2015
- CNS targeting AAV vectors and methods of use thereof57US 9,701,984 B2University of Massachusetts · 2017
- Selective recovery11US 10,202,425 B2California Institute of Technology · 2019
- Selective recovery11US 9,957,303 B2California Institute of Technology · 2018